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Purpose of the study: In recent years there were growing research regarding interventions in first-episode psychosis and patients with high risk for psychosis. 
Consequences are building of early intervention teams and hoped best care to psychotic patients on early phases. There are published guidelines regarding mainly 
treatment but few about diagnosis and medical work-up in first-episode psychosis. There are no single approach to medical work-up in first-episode psychosis but 
clinicians who diagnosis and treat first-episode psychosis patients should reflect on what kind of medical investigation should do. Once the diagnosis of psychotic illness, 
like schizophrenia, implicates absence of a medical condition that could account for the clinical picture a medical work-up is important to the diagnosis. The diagnosis of 
psychotic disorder also implies the subsequent treatment with antipsychotic medication and initial work-up has also the aim to ensure the safety in its use. Initial medical 
evaluation also make a baseline to allow monitoring of iatrogenic morbidity (metabolic problems and movement disorders). Hospital Vila Franca de Xira is a general 
hospital in the metropolitan area of Lisbon, Portugal, which provides medical care to a population of 245.000 persons. Department of Psychiatry is new in the hospital 
which begin its activity in April 2013.  
Methods:  A retrospective study of non-affective first-episode psychosis patients admitted to the Department of Psychiatry of Hospital Vila Franca de Xira between 
April 2013 and March 2015. Electronic files of each patient were analyzed  and initial medical work-up studied. All medical studies including blood tests, toxicology 
screen, neuro-imaging and electrophysiological exams made were registered.  Data were analyzed using IBM SPSS (Statistical Package for the Social Sciences) Statistics 
software version 21.  
Results: Thirty patients diagnosed by their Psychiatrists as first-episode psychosis were 
included. Demographic and clinical characteristics are mentioned in table 1. All patients 
had at least some laboratory tests, 15 patients made toxicological screening test, 23 
cranial computed tomography (CT scan),  2 head magnetic resonance imaging (MRI) and 1 
electroencephalogram (EEG). Between laboratory tests, complete blood count (CBC), 
fasting blood glucose, electrolytes, renal function tests (BUN/creatinine) and liver function 
tests were made in all patients. Twenty-three patients underwent thyroid function tests, 
18 lipid profile, 20 test for syphilis, 18 HIV test, 15 hepatitis C test and 11 hepatitis B test. 
Sixteen patients had vitamin B12 and acid folic dosing. None of the female patients made 
a pregnancy test.  Mean an standard deviation (SD) from  laboratory tests are mentioned 
in table 2. Regarding the results none of the patients had abnormalities in CBC, 
electrolytes or renal function tests. One patient had abnormalities in fasting glucose (132 
mg/dL). Four patients had elevated AST (mean: 62 UI/L; SD: 25.44), 2 patients elevated 
ALT (mean: 123.5 UI/L; SD: 21.92) and 1 patient abnormal GGT (403 UI/L). Acid folic level 
was below normal range in 6 patients (mean: 2.1 ng/mL; SD: 0.58) and vitamin B12 in 4 
patients (mean: 245 pg/mL; SD: 18.65). Total cholesterol abnormalities were found in 6 
patients (mean: 208.17 mg/dL; SD: 10.44) and triglycerides in 3 patients (mean: 179 
mg/dL; SD: 21.93). Six patients had positive toxicological screening for cannabis and 1 for 
cocaine. In neuroimaging cranial TC was done in 23 of the 30 patients studied. Nine 
patients revealed abnormalities: 1 patient ventricular asymmetry; 1 plagiocephaly; 2 
frontal sulci accentuation; 2 parietal sulci accentuation; 1 calcification of cerebral sickle; 1 
probable arachnoid granulation and 1 enlargement of perivascular interstitial just-atrial 
space. Of the 30 patients 2 made a head MRI to clarify some doubts in cranial CT but 
results did not reveal significant abnormalities. One patient made an EEG which was in 
normal range. 
Table 1. Demographic and clinical characteristics of participants  
Gender 
    Male % (n) 
    Female % (n) 
 
Mean age (years) (SD) 
DUP (days) (SD) 
Married  % (n) 
Employed  %(n) 
Students % (n) 
 
Psychiatric Family History 
 
Diagnosis  % (n) 
Schizophrenia/schizophreniform disorder 
Other Specified Schizophrenia Spectrum and  
Other Psychotic disorder 
Brief psychotic disorder 
Delusional disorder 
Cannabis induced psychotic disorder 
 
In-stay % (n) 
 
Treatment % (n) 
First-generation antipsychotics  
Haloperidol 
Zuclopentixole depot 
Second-generation antipsychotics  
Risperidone 
Paliperidone 
Olanzapine 
Aripiprazole 
 
Risperidone long acting injectable 
Paliperidone  palmitate injectable  
 
33.3 (10) 
66.6 (20) 
 
29.8 (9.2) 
520.7 (790.13) 
  16.7 (5) 
  30 (9) 
20 (6) 
 
 53.3 (16) 
 
 
20 (6) 
33.3 (10) 
 
 3.3 (1) 
 3.3 (1) 
30 (9) 
 
 70 (21) 
 
 
 
3.3 (1) 
3.3 (1) 
 
 36.7 (11) 
  6.7 (2) 
 23.3 (7) 
 6.7 (2) 
 
3.3 (1) 
 10 (3)  
Table 4.  Some current guidelines regarding work-up in first-episode psychosis 
NICE 
2013 
UK 
Australian and New Zealand 
clinical practice guidelines 
2005 
Australia and New Zealand  
Canadian Psychiatric 
Association, 2005 
Canada 
 
American Psychiatric Association, 
2004 
USA 
 
Physical Exam 
 
 
 
 
Laboratory tests 
 
 
 
 
 
 
 
 
 
 
Neuroimaging  (NICE, 2008) 
 
 
 
 
Neurophysiology/Neurocognitive 
assessment 
 
Medical monitoring 
Medical history and full physical 
examination, weight, waist 
circumference, pulse, blood 
pressure  
 
Fasting blood glucose, 
glycosylated hemoglobin 
(HbA1c), blood lipid profile and 
prolactin levels 
 
ECG if indicated 
 
 
 
 
 
CT or MRI  not 
recommended as a routine part 
of the initial investigations; only 
performed if indicated by 
clinical picture 
 
 
Follow-up overall physical 
health 
Weight and waist circumference 
Pulse and blood pressure 
Fasting blood glucose, HbA1c 
and  lipid profile 
Physical exam including 
neurological exam, weight and 
height/body mass index 
 
 
Fasting glucose (and/or HbA1c), 
lipid profile, toxicology screen 
 
 
 
 
 
 
 
 
 
MRI 
 
 
 
 
Neurocognitive assessment 
 
Full physical check-ups, 
including weight, blood 
pressure, lipid profile, ECG, and 
fasting blood glucose 
Physical exam including 
neurological exam, vital signs, 
body mass index, waist 
circumference 
 
Complete blood count, 
electrolytes, renal and liver 
function tests 
Thyroid function tests 
Syphilis test 
Hepatitis tests, if indicated 
HIV test, if indicated 
Toxicology screen 
 
 
 
CT or MRI 
 
 
 
 
 
 
Fasting glucose, lipid profile 
ECG 
Prolactin level if clinically 
indicated 
Evaluate for potential 
extrapyramidal symptoms 
Ocular evaluation 
Physical exam including neurological 
exam, vital signs, weight and 
height/body mass index 
 
 
Complete blood count, electrolytes, 
BUN/creatinine, liver function tests 
Thyroid function tests 
Pregnancy test (women of child-
bearing age) 
Syphilis test 
Hepatitis C if indicated 
HIV, if indicated 
Toxicology screen 
Heavy metal screen if indicated 
 
CT or MRI if indicated 
 
 
 
 
Electroencephalogram if indicated 
 
Fasting glucose, lipid profile 
ECG if indicated 
Prolactin level if indicated 
Evaluate for potential extrapyramidal 
symptoms 
Ocular evaluation if indicated 
Table 2. Laboratory tests included on the initial medical work-up of the participants 
Laboratory Tests (Units) Number 
of 
patients 
performed 
N 
Results 
 
Normal 
Range 
 
Haemoglobin (g/dL) 
Haematocrit (%) 
Leukocytes (103 /µL) 
Platelets (103 /µL) 
 
Glucose (mg/dl) 
AST (UI/L) 
ALT (UI/L) 
GGT (UI/L) 
BUN (mg/dl) 
Creatinine (mg/dl) 
 
Sodium (mmol/L) 
Potassium (mmol/L) 
Chloride (mmol/L) 
 
Total Cholesterol (mg/dl) 
HDL (mg/dl) 
LDL (mg/dl) 
Triglycerides (mg/dl) 
 
Acid Folic (ng/mL) 
Vitamin B12 (pg/mL) 
 
Thyroid Stimulating Hormone (mUI/L) 
Free T4 (ng/dL) 
 
HIV test 
Syphilis test 
Hepatitis B 
Hepatitis C 
 
Toxicology screening 
Cannabis 
Cocaine 
Amphetamine/Methamfetamine 
Opiates 
 
30 
30 
30 
30 
 
30 
30 
30 
30 
30 
30 
 
30 
30 
30 
 
18 
18 
18 
18 
 
16 
16 
 
23 
23 
 
18 
20 
11 
15 
 
 
15 
15 
15 
15 
Mean (SD)  
14.31 (1.38) 
42.52 (4.54) 
7.89  (2.72) 
249.58 (77.32) 
 
88,03 (11.36) 
25,11 (19.02) 
36.65 (28.29) 
49.58 (91.96) 
30 (11.45) 
0.89 (0.18) 
 
139.58 (2.27) 
4.22 (0.43) 
103.44 (2.84) 
 
164.88 (35.52) 
47.64 (17.28) 
98.5 (33.65) 
86.35 (48.32) 
 
4.76 (2.80) 
391.55 (166.21) 
 
1.47 (0.67) 
1.18 (0.18) 
 
All negative 
All negative 
All negative 
All negative 
 
 
Positive in 6 patients 
Positive in 1 patient 
All negative 
All negative 
 
13.6-18.0 
39.8-52.0 
4.0-10.0 
140-440 
 
70-110 
10-41 
24-54 
5-55 
19.3-44.9 
0.70-1.30 
 
136-146 
3,5-5 
95-108 
 
<190 
28-72 
<115 
32-134 
 
3.0-17.0 
193.0-982.0 
 
0.35-5.5 
0.80-1.76 
     Conclusions: There is no optimal work-up in first-episode 
psychosis, it should be individualized regarding medical history and 
clinical picture. However general guidelines regarding tests in first-
episode psychosis could help to standardize the evaluation of these 
patients. In our sample of first-episode psychosis patients no medical 
causes for psychosis were found, but abnormalities in laboratory 
findings affected the choice of psychopharmacological treatment. Table 
3 shows our proposal for medical work-up in first-episode psychosis. 
Finally table 4 summarizes main current guidelines. 
Discussion: Initial medical work-up in patients with first-episode psychosis has two main aims: 1)Exclude medical treatable disorders that could be 
responsible for psychotic symptoms; 2)Establishing the presence of relevant medical comorbidities (particularly important in patients who are in the 
beginning of psychopharmacological treatment). A problem is the differentiation between comorbidity and causality that exists in psychotic disorders. 
Even if a disorders/disease is discovered it is not linear that it is aetiologically relevant. Even when comorbidity is in question, it is important to 
diagnose it. Usually it has a negative impact in disorder. Our results illustrates that there is no consensus regarding medical work-up in first-episode 
psychosis. In the sample studied no organic cause was found for the psychotic disorder but some abnormalities exist. The main abnormality found 
were changes in lipid profile, namely in total cholesterol and triglycerides, which has impact on the antipsychotic medication chosen. In some patients 
the dosing of acid folic and vitamin B12 was below normal range but the exact meaning of this finding to the first-episode psychosis is quite difficult to 
determine precisely. However all of these patients received supplementation. Psychotic patients are considered high risk patients to infectious 
diseases but none of the patients in our sample had some of these analyses positive (HIV, syphilis and hepatitis B and C).  We also found some 
abnormalities in cranial CT however none of the findings was attributed a causal link with psychotic disorder. Regarding neuroimaging 77% patients 
made an exam. In our sample the cranial CT was the neuroimaging technical elect for the majority of the patients. As our results reflect, majority of 
first-episode psychosis patients will not have identifiable disorders by neuroimaging with etiological relevance. We also agree with other authors that 
even a negative scan is important establishing the “functional” character of the disorder and can help patients and their families towards acceptance 
of a psychiatric disorder. Only in 50% (n=15) of the first-episode psychosis patients toxicology screening was done, which is quite low considering high 
rates of cannabis use in this population. Seven (>50%) patients of these had positive results for cannabis or cocaine. The low specificity of EEG and the 
medication-induced EEG changes are problems which is not advice to consider it to all first-episode psychosis patients. In our view EEG should be 
ordered only in patients where seizures are suspected (e.g.: history suggestive of seizures or ictal events, past head injury etc.) or suspicion of 
narcolepsy.  
Table 3. Medical work-up in first-episode 
psychosis  
Physical Exam (including neurological exam) 
Vital signs 
Weight, height, BMI, waist circumference 
 
ECG (if cardiac risk) 
 
Laboratory tests 
Complete blood count 
Renal function tests 
Liver function tests 
Electrolytes 
Fasting glucose 
Lipid profile 
TSH, fT4 
Syphilis serology 
HIV test 
Vitamin B12 
 
Neuroimaging 
Magnetic resonance imaging (prefered over CT) 
 
Considered if indicated by clinical picture 
Electroencephalogram (EEG) 
Heavy metal testing 
Chest X-ray 
Lumbar puncture 
Adaptated from Freudenreich, O et al., 2009 
